Drugs / DO-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05752552 | Dec 2022 → Sep 2027 expected | hereditary papillary renal cell carcinoma, non-small cell lung carcinoma | DeuterOncology | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | DeuterOncology | Results Promising Phase I Results for DO-2 MET Kinase Inhibitor deuteroncology.com ↗
RECIST 1.1 Partial responses (>30% reduction) were observed in 2 out of these 10 patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | DeuterOncology | Promising Phase I Results for DO-2 MET Kinase Inhibitor deuteroncology.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DO-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05752552 ↗ |
| Action | Inhibit | “Deuterated MET kinase inhibitor” NCT05752552 ↗ |
| Route | Oral | “Oral administration” NCT05752552 ↗ |
| Target | MET | “Deuterated MET kinase inhibitor” NCT05752552 ↗ |